Sino Biopharmaceut (OTCMKTS:SBMFF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Shares of Sino Biopharmaceut (SBMFF) traded up $0.06 during trading on Thursday, reaching $1.83. The company had a trading volume of 1,400 shares, compared to its average volume of 15,166. Sino Biopharmaceut has a fifty-two week low of $0.72 and a fifty-two week high of $1.80.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Downgrades Sino Biopharmaceut (SBMFF) to Hold” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at

Sino Biopharmaceut Company Profile

Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.

Get a free copy of the Zacks research report on Sino Biopharmaceut (SBMFF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with's FREE daily email newsletter.